Michael Adam Gordon's most recent trade in Lucid Diagnostics Inc was a trade of 300,000 Common stock done . Disclosure was reported to the exchange on Feb. 20, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Lucid Diagnostics Inc | Michael Adam Gordon | General Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2026 | 300,000 | 1,000,000 | - | 0 | Common stock | |
| PAVmed Inc | Michael Adam Gordon | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2025 | 150,000 | 150,000 (0%) | 0% | 0 | Common Stock | |
| Lucid Diagnostics Inc | Michael Adam Gordon | General Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 300,000 | 700,000 | - | 0 | Common stock | |
| Lucid Diagnostics Inc | Michael Adam Gordon | General Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2024 | 400,000 | 400,000 | - | 0 | Common stock | |
| PAVmed Inc | Michael Adam Gordon | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2022 | 400,000 | 400,000 | - | - | Employee stock option (right to buy) | |
| Lucid Diagnostics Inc | Michael Adam Gordon | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2022 | 200,000 | 200,000 | - | - | Employee stock option (right to buy) |